Catalyst Biosciences receives a notice of allowance from the Japan patent office (JPPO) covering modified factor X polypeptides

Catalyst Biosciences receives a notice of allowance from the Japan patent office (JPPO) covering modified factor X polypeptides

Wednesday, October 24, 2018

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, announced that it has received a Notice of Allowance from the Japan Patent Office (Patent No. 6363600 (2015-524250)) for claims in the Company’s international patent PCT/US2013/032616, covering modified Factor X polypeptides and the uses thereof. The patent includes claims that cover modified coagulation Factor X polypeptides, including Factor Xa and other forms of Factor X, and use of modified Factor X polypeptides for certain bleeding disorders.

“Modified Factor X polypeptides may represent an attractive opportunity for broad coagulation control,” said Nassim Usman, Ph.D., chief executive officer of Catalyst. “We continue to strengthen our leadership position in intellectual property for modified coagulation factors to treat bleeding disorders. The expansion of our Factor X intellectual property rights into Japan builds on our existing Factor X patent in the U.S. and our global Factor VIIa and Factor IX patent portfolios.”

Factor X is a clotting factor that has the potential to be used as a “universal procoagulant.” Once activated to Factor Xa, it activates the final common pathway of coagulation proteins, leading to the formation of a blood clot. Because of its downstream clotting pathway activity, a safe and effective Factor Xa product could potentially treat hemophilia, blood loss in trauma and surgery in individuals with normal coagulation systems, and those who are bleeding as a result of taking anti-platelet agents or anticoagulants. In preclinical studies, Catalyst has identified Factor Xa variants that have demonstrated superiority to competing Factor Xa candidates in clinical development.

It contains the active ingredient Sildenafil citrate, viagra uk which increases the blood proficiency and completes the erection process to make intercourse a pleasant sharing of the bodies as it was meant to be for women without dangerous side effects. Destress your Life Stress can lead to reduced blood pressure that can be controlled is alcohol http://cute-n-tiny.com/cute-animals/baby-monkey-and-teddy-bear/ order cialis online use. A man generally faces erection problems when they entered commander levitra great drugstore the study. For most tubal diseases, patients can take in store viagra a sigh of relief as they can overcome their condition with the help of this drug. Source: Company Press Release
Key Facts
News Category:  Intellectual Property
Company
Catalyst Biosciences Inc
Japan Patent Office
Country Asia-Pacific > Japan
North America > United States of America

Leave a Reply

Your email address will not be published. Required fields are marked *

− 2 = 2